Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Toxoplasmosis

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

Disorders of the Female Reproductive System

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

Trichomoniasis

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Balancing fertility potential and oncologic and obstetric risks: a vignette study on decision-making in fertility-sparing surgery for early-stage cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Same author

Radiation therapy and cancer during pregnancy - Current practice in the Netherlands.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Same author

Diagnostic accuracy of ultrasound models for assessment of ovarian tumors: systematic review and meta-analysis.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025

Same author

The risk for residual AIS/CIN3+ after the first conservative surgical procedure for cervical adenocarcinoma in situ - A Dutch retrospective cohort study.

Gynecologic oncology·2025

Same author

Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.

Gynecologic oncology·2025

Same author

Current uptake and barriers to wider use of the International Ovarian Tumor Analysis (IOTA) models in Dutch gynaecological practice.

European journal of obstetrics, gynecology, and reproductive biology·2023

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta

A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta

Published on: September 27, 2017

[Trophoblastic diseases].

M J ten Kate-Booij¹, C A R Lok, R H M Verheijen

¹Amphia Ziekenhuis, locatie Langendijk, afd. Obstetrie en Gynaecologie, Langendijk 75, 4819 EV Breda. mtkate@amphia.nl

Nederlands Tijdschrift Voor Geneeskunde

|November 18, 2008

Summary

This summary is machine-generated.

Gestational trophoblastic disease (GTD) management involves monitoring human chorionic gonadotrophin (HCG) levels. Methotrexate is the primary treatment for persistent GTD, with combination therapy reserved for resistant cases or choriocarcinoma.

More Related Videos

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 28, 2026

A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta

A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta

Published on: September 27, 2017

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

Area of Science:

Gynecology
Oncology
Endocrinology

Context:

Hydatidiform mole is the most common gestational trophoblastic disease (GTD).
Elevated human chorionic gonadotrophin (HCG) signifies GTD.
Post-molar HCG monitoring is crucial for diagnosing persistent GTD.

Purpose:

To outline the diagnostic and therapeutic strategies for gestational trophoblastic disease (GTD).
To detail the role of human chorionic gonadotrophin (HCG) monitoring in GTD management.
To describe treatment protocols for persistent GTD and choriocarcinoma.

Summary:

Gestational trophoblastic disease (GTD) is characterized by elevated human chorionic gonadotrophin (HCG).
Persistent GTD is diagnosed via HCG regression curves post-molar evacuation.
Methotrexate monochemotherapy is the first-line treatment, achieving remission in 80% of cases.
Combination therapy is indicated for methotrexate resistance or choriocarcinoma.
Hysterectomy or curettage may be used in select cases.

Impact:

Establishes standardized monitoring and treatment protocols for GTD.
Improves patient outcomes through timely and appropriate therapeutic interventions.
Highlights the need for specialized centers for managing high-risk GTD cases like choriocarcinoma.